Volume Spike Investor

Sequenom Inc. (NASDAQ: SQNM) is getting hit this morning on allegations from an outside group called Xenomics, Inc.  Xenomics said “an ongoing internal investigation by Xenomics’ personnel of the events surrounding its licensing deal with Sequenom in late October, 2008 leads it to conclude that Sequenom purposely misled the Company – fraudulently inducing Xenomics into granting Sequenom an exclusive license to its transrenal technology. Sequenom’s announced success in developing a Down Syndrome test in late 2008 was the principal factor in Xenomics’ decision to exclusively license its core Transrenal DNA and RNA technology in the area of fetal diagnostics to Sequenom.”

Needless to say, this is hitting Sequenom as it is re-confirming or at least re-stimulating those fears that officers of Sequenom were tampering with test results.  At 8:43 AM EST Sequenom shares are down 8.8% at $3.81 on 226,000 shares.

JON OGG